Tier Seven identifies technologies that improve operational readiness, situational awareness and healthcare delivery for our warfighters
DoD NON-DILUTIVE FUNDING
Unique and proven processes for delivering DoD R&D resources
COOPERATIVE R&D AGREEMENTS (CRADAs)
Tier Seven’s report on how CRADAs with DoD Researchers can bring
your technology to the DoD
HUMAN SYSTEMS TECHNOLOGIES
Annual DoD human weapon system technology focus areas
Tier Seven identifies biomedical technologies that can improve the delivery of health care for our active duty personnel, veterans, and their families.
Proven DoD Strategic Roadmaps.
Cooperative R&D Agreements (CRADAs)
Science Advisory Services
In 2015, over $2.6M in non-dilutive and dilutive funding awards
In 2016, clients were awarded $4.5M in non-dilutive funding
In 2015, 75% of full application DoD non-dilutive submissions received awards
$1.5M in CRADA value for the DoD and Industry
Dr. Hanson was instrumental in Sonivate Medical receiving $2.5 million in funding from the US Army to develop an ultrasound system focused on emergency medicine including the forward deployment. He guided us through the whole proposal process and especially ensured that we included the Training Development and the Assessments for the medics. As it turned out, the Assessments were vital documents in our 510k submission to the FDA to establish a predicate product. Eric’s sections in the proposal received Sonivate’s highest ratings.
Thanks to Dr. Hanson, and most recently the FDA clearance, we are now well on our way to offer this needed product to our military and emergency medicine worldwide.
James Hatlan, President and CEO, Sonivate Medical, Inc.
Dr. Hanson recently assisted us in preparing a Phase I Small Business Innovation Research (SBIR) grant for a medical device to prevent catheter associated infections. Originally, I assumed his input would be limited, helping us make sure that we clearly conveyed our proposal. He did much more than that.He transformed all aspects of the proposal by helping us understand how to articulate the significance of our innovation and the precise steps we were proposing to accomplish that. This required an understanding of our short term and long term goals, the risks we faced, and how completing the research aims would accelerate our 510(k) pathway to market.
I will not be filing any additional grants without Dr. Hanson’s assistance and my team thoroughly enjoyed working with him.